Anixa Biosciences Completes Final Patient Visits in Breast Cancer Vaccine Trial; Full Results to Be Presented at December Symposium
Reuters
Oct 07, 2025
<a href="https://laohu8.com/S/ANIX">Anixa Biosciences</a> Completes Final Patient Visits in Breast Cancer Vaccine Trial; Full Results to Be Presented at December Symposium
Anixa Biosciences Inc. has announced the completion of the final patient visit in its Phase 1 clinical trial evaluating a novel breast cancer vaccine developed in collaboration with Cleveland Clinic. The vaccine, designed to stimulate the immune system to recognize and target breast cancer, was administered to 35 women across three cohorts: individuals with a history of triple-negative breast cancer (TNBC), women at elevated genetic risk who elected preventive mastectomy, and patients receiving the vaccine in combination with pembrolizumab. Preliminary data indicate the vaccine is well tolerated, with more than 70% of participants showing protocol-defined immune responses. Comprehensive immune response and safety data from the trial will be presented at the San Antonio Breast Cancer Symposium on December 11, 2025. A final study report will be submitted to the U.S. Department of Defense, and a Clinical Study Report will be filed with the U.S. Food and Drug Administration.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Anixa Biosciences Inc. published the original content used to generate this news brief via PR Newswire (Ref. ID: LA91771) on October 07, 2025, and is solely responsible for the information contained therein.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.